Sol Gel Technologies Ltd 's Leverage Ratio

SLGL's quarterly Leverage Ratio and Total Liabilities, Equity growth

Due to repayements of liabilities of 0% Sol Gel Technologies Ltd improved Leverage Ratio in forth quarter 2023 to 0.17, below the company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 51 other companies have achieved lower Leverage Ratio than Sol Gel Technologies Ltd in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 271, from total ranking in the third quarter 2023 at 451 .

Explain Leverage Ratio?
Who are SLGL Customers?
What are SLGL´s Total Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Leverage Ratio ▼

None ▼

Leverage Ratio ▼

SLGL Leverage Ratio	(Dec 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Equity Change	-8.45 %	-8.45 %	-8.45 %	-8.45 %	-24.07 %
Y / Y Total Liabilities Change	50.46 %	50.46 %	50.46 %	50.46 %	-65.55 %
Leverage Ratio MRQ	0.17	0.17	0.17	0.17	0.1
SLGL's Total Ranking	# 271	# 451	# 502	# 532	# 297
Seq. Equity Change	0 %	0 %	0 %	-8.45 %	0 %
Seq. Total Liabilities Change	0 %	0 %	0 %	50.46 %	0 %

New: More SLGL's historic Leverage Ratio results >>

Leverage Ratio forth quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 52
Healthcare Sector	# 98
Overall Market	# 271

Leverage Ratio Statistics
High	Average	Low
0.23	0.17	0.1
(Dec 31 2021)		(Dec 31 2022)

Financial Statements
Sol Gel Technologies Ltd 's Equity	$ 39 Millions	Visit SLGL's Balance sheet
Sol Gel Technologies Ltd 's Total Liabilities	$ 7 Millions	Visit SLGL's Balance sheet
Source of SLGL's Sales		Visit SLGL's Sales by Geography

Cumulative Sol Gel Technologies Ltd 's Leverage Ratio

SLGL's Leverage Ratio for the trailling 12 Months

SLGL Leverage Ratio	(Dec 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Equity TTM Growth	-8.45 %	-8.45 %	-8.45 %	-8.45 %	-24.07 %
Y / Y Total Liabilities TTM Growth	50.46 %	50.46 %	50.46 %	50.46 %	-65.55 %
Leverage Ratio TTM	0.17	0.15	0.14	0.12	0.1
Total Ranking TTM	# 119	# 0	# 0	# 0	# 3
Seq. Equity TTM Growth	0 %	0 %	0 %	-8.45 %	0 %
Seq. Total Liabilities TTM Growth	0 %	0 %	0 %	50.46 %	0 %

Leverage ratio ranking by company, industry and sector >> Back to SLGL Financial Strength Comparisons >> Compare SLGL Leverage Ratio to its Peers

On the trailing twelve months basis Despite of the repayements of liabilities of 0% in the trailing twelve months ending in IV Quarter 2023, Leverage Ratio improved to 0.17, below Sol Gel Technologies Ltd 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 25, during the past 12 months, other companies have achieved lower Leverage Ratio than Sol Gel Technologies Ltd . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 0 to 119.

Explain Leverage Ratio?
Who are SLGL Customers?
What are SLGL´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 26
Healthcare Sector	# 47
Within the Market	# 119

trailing twelve months Leverage Ratio Statistics
High	Average	Low
0.24	0.18	0.1
(Dec 31 2021)		(Dec 31 2022)

Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry	Leverage Ratio	Dec 31 2023 MRQ Total Liabilities	Dec 31 2023 MRQ Equity
Shuttle Pharmaceuticals Holdings Inc	0.47	$ 1.896 Millions	$ 4.056 Millions
Moleculin Biotech Inc	0.47	$ 12.144 Millions	$ 26.073 Millions
Schrodinger Inc	0.46	$ 254.397 Millions	$ 548.558 Millions
Tonix Pharmaceuticals Holding Corp	0.46	$ 48.932 Millions	$ 105.525 Millions
Guardion Health Sciences Inc	0.46	$ 3.772 Millions	$ 8.146 Millions
Affimed N v	0.45	$ 29.016 Millions	$ 64.744 Millions
Talphera Inc	0.45	$ 6.290 Millions	$ 14.105 Millions
Pieris Pharmaceuticals Inc	0.45	$ 11.922 Millions	$ 26.758 Millions
Tenax Therapeutics Inc	0.44	$ 3.587 Millions	$ 8.098 Millions
Genprex Inc	0.44	$ 3.254 Millions	$ 7.416 Millions
Xencor Inc	0.42	$ 283.896 Millions	$ 669.133 Millions
Arrowhead Pharmaceuticals Inc	0.42	$ 73.609 Millions	$ 173.714 Millions
Salarius Pharmaceuticals inc	0.41	$ 2.192 Millions	$ 5.287 Millions
Medicure Inc	0.41	$ 6.253 Millions	$ 15.240 Millions
Avenue Therapeutics Inc	0.41	$ 0.268 Millions	$ 0.654 Millions
Oncolytics Biotech Inc	0.41	$ 8.623 Millions	$ 21.113 Millions
Xilio Therapeutics Inc	0.40	$ 14.910 Millions	$ 36.827 Millions
Anaptysbio Inc	0.40	$ 35.665 Millions	$ 88.103 Millions
Arcus Biosciences Inc	0.40	$ 184.000 Millions	$ 462.000 Millions
Neurobo Pharmaceuticals Inc	0.40	$ 6.618 Millions	$ 16.685 Millions
Telomir Pharmaceuticals Inc	0.39	$ 1.336 Millions	$ 3.438 Millions
Integrated Biopharma Inc	0.39	$ 7.155 Millions	$ 18.566 Millions
Biomarin Pharmaceutical Inc	0.38	$ 1,890.054 Millions	$ 4,951.549 Millions
Benitec Biopharma Inc	0.38	$ 5.883 Millions	$ 15.470 Millions
Renovaro Inc	0.37	$ 16.328 Millions	$ 43.596 Millions
Gain Therapeutics inc	0.37	$ 4.679 Millions	$ 12.578 Millions
Abivax Sa	0.36	$ 78.447 Millions	$ 219.531 Millions
Pharming Group N v	0.36	$ 77.968 Millions	$ 218.781 Millions
Fsd Pharma Inc	0.35	$ 4.566 Millions	$ 12.909 Millions
Context Therapeutics Inc	0.35	$ 4.192 Millions	$ 11.871 Millions

Date modified: 2024-03-13T18:38:06+00:00

Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com